Earnings

Dyne Therapeutics Q3 EPS $(1.06) Misses $(0.92) Estimate

Nov 5, 2026 · 08:37 AM ET· updated 1h ago

Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.92) by 15.22 percent. This is a 39.47 percent decrease over losses of $(0.76) per share

Why It Matters

Dyne Therapeutics lost more money per share than expected this quarter. When a company loses more than people thought, it shows the business is burning cash faster than planned.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

DYN18.12

-0.42 (-2.27%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.